Aurinia Pharmaceuticals (AUPH) EBT (2019 - 2026)
Aurinia Pharmaceuticals' (AUPH) quarterly EBT came in at $43.9 million in Q1 2026, up 80.4% YoY from $24.3 million in Q1 2025, and up 23.07% on a QoQ basis from $35.7 million in Q4 2025.
Aurinia Pharmaceuticals (AUPH) EBT (2019 - 2026) Analysis & Trends
Aurinia Pharmaceuticals (AUPH) has 8 years of EBT data on file, last reported at $43.9 million in Q1 2026.
- Quarterly EBT rose 80.4% year-over-year to $43.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $133.7 million (up 219.88% YoY) and the FY2025 annual result came in at $114.2 million, up 1432.72% from the prior year.
- EBT rose to $43.9 million in Q1 2026, from $35.7 million in the prior quarter.
- In the past five years, EBT ranged from a high of $43.9 million in Q1 2026 to a low of -$37.6 million in Q1 2022.
- A 5-year average of -$1.1 million and a median of -$8.0 million in 2022 frame the typical range for EBT.
- Annual changes were most pronounced in 2023 — EBT sank 63.65% — and 2025, when it soared 2942.63%.
- Tracing AUPH's EBT over 5 years: stood at -$25.2 million in 2022, then fell by 4.86% to -$26.4 million in 2023, then surged by 104.44% to $1.2 million in 2024, then soared by 2942.63% to $35.7 million in 2025, then rose by 23.07% to $43.9 million in 2026.
- The last three EBT figures came in at $43.9 million (Q1 2026), $35.7 million (Q4 2025), and $32.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Aurinia Pharmaceuticals | 2.06 Bn | 1.61 Bn | 76.67 Mn | 48.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 48.79 Mn |
| Mar 31, 2026 | 43.93 Mn |
| Dec 31, 2025 | 35.69 Mn |
| Sep 30, 2025 | 31.96 Mn |
| Jun 30, 2025 | 22.16 Mn |
| Mar 31, 2025 | 24.35 Mn |
| Dec 31, 2024 | 1.17 Mn |
| Sep 30, 2024 | 14.81 Mn |
| Jun 30, 2024 | 1.48 Mn |
| Mar 31, 2024 | -10.01 Mn |
| Dec 31, 2023 | -26.42 Mn |
| Sep 30, 2023 | -13.15 Mn |
| Jun 30, 2023 | -12.13 Mn |
| Mar 31, 2023 | -25.77 Mn |
| Dec 31, 2022 | -25.19 Mn |
| Sep 30, 2022 | -8.04 Mn |
| Jun 30, 2022 | -35.51 Mn |
| Mar 31, 2022 | -37.62 Mn |
| Dec 31, 2021 | -32.60 Mn |
| Sep 30, 2021 | -50.25 Mn |